Current Atherosclerosis Reports

Papers
(The H4-Index of Current Atherosclerosis Reports is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Revascularization Options for Left Main Disease: What Clinicians Need to Know121
Are Clinicians Aggressive Enough in Treating Diabetes-Related Hyperlipidemia in Youth?113
The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes103
Polysocial Risk Scores: Implications for Cardiovascular Disease Risk Assessment and Management88
A Narrative Review of the Association Between Depression and Heart Disease Among Women: Prevalence, Mechanisms of Action, and Treatment68
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions66
Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?65
The Greatly Under-Represented Role of Smooth Muscle Cells in Atherosclerosis64
The Effects of FABP4 on Cardiovascular Disease in the Aging Population63
Heart Transplant, Kawasaki Disease, and Bone Marrow Transplant: Are There Consequences?63
Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management63
Anti-apoC-III Therapies and Implications for Treatment of Pancreatitis and Cardiovascular Disease56
The Role of the PI3K/Akt/mTOR Pathway in Atherosclerosis: Mechanisms, Therapeutic Potential, and Emerging Targeted Treatments55
Effects of Pioglitazone On Lipoprotein(a): A Meta-analysis54
Salutary Effects of Nutritional Ketosis for the Diseased Human Heart54
PCSK9 Inhibition and Risk of Diabetes: Should We Worry?54
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond47
From ‘Omics to Multi-omics Technologies: the Discovery of Novel Causal Mediators47
Genetic Testing for Familial Hypercholesterolemia in Clinical Practice46
DOACs and Atherosclerotic Cardiovascular Disease Management: Can We Find the Right Balance Between Efficacy and Harm45
Polypharmacy and Cardiovascular Diseases: Consideration for Older Adults and Women44
Spontaneous Coronary Artery Dissection (SCAD): Unveiling the Enigma of the Unexpected Coronary Event43
The Emerging Specialty of Cardio-Rheumatology39
Recent Advances and Perspectives of Metabolomics-Based Investigations in Coronary Heart Disease37
Nutrition Interventions for Youth with Dyslipidemia: Who, What, When, and Where?37
Correction to: Beta‑blockers for Atherosclerosis Prevention: a Missed Opportunity?37
Percutaneous Coronary Interventions in Women35
Inflammation in the Peri-ACS Period: Ready for Prime Time?35
Myeloid Cells in Abdominal Aortic Aneurysm35
The Intersection Between COVID-19, Cardiovascular Disease, and Diet: a Review34
The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention34
The Role of Sleep in Cardiovascular Disease32
GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?32
0.26300287246704